Does the media refer more to KMDA or LKFT?

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Kamada. Kamada's average media sentiment score of 1.13 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakefront Biotherapeutics American Depositary Shares 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, KMDA or OCUL?

Kamada has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.39 $20.20M $0.35 21.41 Ocular Therapeutix $52.04M 34.99 -$265.94M -$1.46 N/A

Does the media favor KMDA or OCUL?

In the previous week, Ocular Therapeutix had 6 more articles in the media than Kamada. MarketBeat recorded 9 mentions for Ocular Therapeutix and 3 mentions for Kamada. Kamada's average media sentiment score of 1.13 beat Ocular Therapeutix's score of -0.19 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, KMDA or VCEL?

Kamada has higher earnings, but lower revenue than Vericel. Kamada is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.39 $20.20M $0.35 21.41 Vericel $276.26M 6.47 $16.52M $0.42 83.39

Is KMDA or VCEL more profitable?

Kamada has a net margin of 11.21% compared to Vericel's net margin of 7.35%. Kamada's return on equity of 7.73% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% Vericel 7.35% 6.41% 4.61%

Does the media favor KMDA or VCEL?

In the previous week, Kamada had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Kamada and 2 mentions for Vericel. Kamada's average media sentiment score of 1.13 beat Vericel's score of 0.93 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, HRMY or KMDA?

Harmony Biosciences has higher revenue and earnings than Kamada. Harmony Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harmony Biosciences $899.11M 2.04 $158.69M $2.48 12.75 Kamada $180.46M 2.39 $20.20M $0.35 21.41

Does the media prefer HRMY or KMDA?

In the previous week, Kamada had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 3 mentions for Kamada and 2 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.26 beat Kamada's score of 1.13 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, KMDA or NTLA?

Kamada has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.39 $20.20M $0.35 21.41 Intellia Therapeutics $66.09M 27.91 -$412.69M -$3.54 N/A

Does the media refer more to KMDA or NTLA?

In the previous week, Kamada and Kamada both had 3 articles in the media. Kamada's average media sentiment score of 1.13 beat Intellia Therapeutics' score of 1.10 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kamada (KMDA) Competitors

$7.50 -0.32 (-4.03%)

As of 12:57 PM Eastern

Compare

KMDA vs. LKFT, OCUL, VCEL, HRMY, and NTLA

Should you buy Kamada stock or one of its competitors? MarketBeat compares Kamada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kamada include Lakefront Biotherapeutics American Depositary Shares (LKFT), Ocular Therapeutix (OCUL), Vericel (VCEL), Harmony Biosciences (HRMY), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.

How does Kamada compare to Lakefront Biotherapeutics American Depositary Shares?

Kamada (NASDAQ:KMDA) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Kamada currently has a consensus target price of $12.00, indicating a potential upside of 60.11%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, indicating a potential upside of 32.53%. Given Kamada's stronger consensus rating and higher possible upside, equities analysts clearly believe Kamada is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

20.4% of Kamada shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kamada has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kamada. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.39	$20.20M	$0.35	21.41
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Kamada. Kamada's average media sentiment score of 1.13 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.61 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has a net margin of 11.21% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Kamada's return on equity of 7.73% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Kamada beats Lakefront Biotherapeutics American Depositary Shares on 12 of the 17 factors compared between the two stocks.

How does Kamada compare to Ocular Therapeutix?

Kamada (NASDAQ:KMDA) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Kamada currently has a consensus target price of $12.00, indicating a potential upside of 60.11%. Ocular Therapeutix has a consensus target price of $23.78, indicating a potential upside of 185.96%. Given Ocular Therapeutix's higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Kamada has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 6 more articles in the media than Kamada. MarketBeat recorded 9 mentions for Ocular Therapeutix and 3 mentions for Kamada. Kamada's average media sentiment score of 1.13 beat Ocular Therapeutix's score of -0.19 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has a net margin of 11.21% compared to Ocular Therapeutix's net margin of -558.24%. Kamada's return on equity of 7.73% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

20.4% of Kamada shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kamada has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.39	$20.20M	$0.35	21.41
Ocular Therapeutix	$52.04M	34.99	-$265.94M	-$1.46	N/A

Summary

Kamada beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Vericel?

Kamada (NASDAQ:KMDA) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kamada has higher earnings, but lower revenue than Vericel. Kamada is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.39	$20.20M	$0.35	21.41
Vericel	$276.26M	6.47	$16.52M	$0.42	83.39

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 60.11%. Vericel has a consensus target price of $55.40, suggesting a potential upside of 58.17%. Given Kamada's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kamada is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kamada has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Kamada had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Kamada and 2 mentions for Vericel. Kamada's average media sentiment score of 1.13 beat Vericel's score of 0.93 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has a net margin of 11.21% compared to Vericel's net margin of 7.35%. Kamada's return on equity of 7.73% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Vericel	7.35%	6.41%	4.61%

Summary

Kamada beats Vericel on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Harmony Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Kamada has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Harmony Biosciences presently has a consensus target price of $40.89, indicating a potential upside of 29.35%. Kamada has a consensus target price of $12.00, indicating a potential upside of 60.11%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Harmony Biosciences has higher revenue and earnings than Kamada. Harmony Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$899.11M	2.04	$158.69M	$2.48	12.75
Kamada	$180.46M	2.39	$20.20M	$0.35	21.41

In the previous week, Kamada had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 3 mentions for Kamada and 2 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.26 beat Kamada's score of 1.13 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 16.20% compared to Kamada's net margin of 11.21%. Harmony Biosciences' return on equity of 17.19% beat Kamada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Kamada	11.21%	7.73%	5.41%

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Harmony Biosciences beats Kamada on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Intellia Therapeutics?

Kamada (NASDAQ:KMDA) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Kamada has a net margin of 11.21% compared to Intellia Therapeutics' net margin of -597.04%. Kamada's return on equity of 7.73% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Kamada has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.39	$20.20M	$0.35	21.41
Intellia Therapeutics	$66.09M	27.91	-$412.69M	-$3.54	N/A

Kamada has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 60.11%. Intellia Therapeutics has a consensus target price of $20.25, suggesting a potential upside of 53.41%. Given Kamada's stronger consensus rating and higher probable upside, equities analysts plainly believe Kamada is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Kamada and Kamada both had 3 articles in the media. Kamada's average media sentiment score of 1.13 beat Intellia Therapeutics' score of 1.10 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20.4% of Kamada shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Kamada beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$449.11M	$3.37B	$6.39B	$12.60B
Dividend Yield	2.40%	2.29%	2.69%	5.30%
P/E Ratio	21.54	18.01	21.14	26.64
Price / Sales	2.39	182.95	513.05	95.52
Price / Cash	12.79	54.19	27.44	37.60
Price / Book	1.60	6.53	9.81	6.79
Net Income	$20.20M	$24.15M	$3.56B	$337.23M
7 Day Performance	-5.72%	-1.39%	0.40%	2.67%
1 Month Performance	-8.71%	1.04%	4.87%	6.66%
1 Year Performance	8.62%	51.35%	31.14%	37.99%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.8597 of 5 stars	$7.50 -4.0%	$12.00 +60.1%	+12.9%	$449.11M	$180.46M	21.54	360	News Coverage
LKFT Lakefront Biotherapeutics American Depositary Shares	2.5916 of 5 stars	$27.58 +0.3%	$36.50 +32.3%	-5.1%	$1.82B	$1.26B	N/A	1,310
OCUL Ocular Therapeutix	2.7208 of 5 stars	$8.22 -0.1%	$23.78 +189.3%	+11.5%	$1.80B	$51.95M	N/A	230
VCEL Vericel	3.3069 of 5 stars	$34.75 +0.1%	$55.40 +59.4%	-21.6%	$1.77B	$276.26M	82.74	300
HRMY Harmony Biosciences	4.6072 of 5 stars	$30.42 +0.9%	$40.89 +34.4%	-7.5%	$1.76B	$868.45M	12.27	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors

KMDA vs. LKFT, OCUL, VCEL, HRMY, and NTLA

How does Kamada compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Kamada compare to Ocular Therapeutix?

Summary

How does Kamada compare to Vericel?

Summary

How does Kamada compare to Harmony Biosciences?

Summary

How does Kamada compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kamada (KMDA) Competitors

KMDA vs. LKFT, OCUL, VCEL, HRMY, and NTLA

How does Kamada compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts recommend KMDA or LKFT?

Do institutionals & insiders believe in KMDA or LKFT?

Which has more volatility and risk, KMDA or LKFT?

Which has preferable valuation and earnings, KMDA or LKFT?

Does the media refer more to KMDA or LKFT?

Is KMDA or LKFT more profitable?

Summary

How does Kamada compare to Ocular Therapeutix?

Do analysts rate KMDA or OCUL?

Which has more risk and volatility, KMDA or OCUL?

Does the media favor KMDA or OCUL?

Is KMDA or OCUL more profitable?

Do insiders & institutionals hold more shares of KMDA or OCUL?

Which has stronger earnings and valuation, KMDA or OCUL?

Summary

How does Kamada compare to Vericel?

Do institutionals and insiders have more ownership in KMDA or VCEL?

Which has higher valuation & earnings, KMDA or VCEL?

Do analysts prefer KMDA or VCEL?

Which has more risk & volatility, KMDA or VCEL?

Does the media favor KMDA or VCEL?

Is KMDA or VCEL more profitable?

Summary

How does Kamada compare to Harmony Biosciences?

Which has more volatility & risk, HRMY or KMDA?

Do analysts prefer HRMY or KMDA?

Which has better valuation & earnings, HRMY or KMDA?

Does the media prefer HRMY or KMDA?

Is HRMY or KMDA more profitable?

Do institutionals & insiders believe in HRMY or KMDA?

Summary

How does Kamada compare to Intellia Therapeutics?

Is KMDA or NTLA more profitable?

Which has better earnings & valuation, KMDA or NTLA?

Which has more risk & volatility, KMDA or NTLA?

Do analysts prefer KMDA or NTLA?

Does the media refer more to KMDA or NTLA?

Do institutionals and insiders have more ownership in KMDA or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools